At Acorn Regulatory we are committed to ensuring quality in all aspects of what we do so it’s vital to… Read more
Minister Simon Harris’ confirmation that the Irish government will soon be making a bid to be the new home of… Read more
We have just launched our new Acorn Regulatory monthly newsletter. You can read all of the stories from the newsletter… Read more
The implications of Brexit are still being felt. Politically, the decision has triggered a chain of events that none of us… Read more
In this month’s roundup of industry news roundup, we will be looking at how the USA and Canada are working… Read more
Right now, we are seeking a consultant to work on-site with our client in the south-east of Ireland. The client is… Read more
In this extract from our first Brexit whitepaper, written in July 2016, we look at the implications of Brexit for… Read more
The European Medicines Agency has added a new chapter (Product- or population-specific considerations II: Biological medicinal products) to its guidelines… Read more
In this extract from our first Brexit whitepaper we look at the implications of Brexit for the clinical trials sector.
In this extract from our first Brexit whitepaper we look at the implications of Brexit for existing marketing authorisations.
Following discussions with industry bodies, the MHRA is now replacing all paper-based communications with emails. The emails will replace paper-based communications… Read more
We are looking at five of the biggest stories in the pharmaceutical, medical devices and clinical trials sectors in the… Read more